ARG is a tyrosine kinase closely related to ABL, which is oncogenic when fused to the transcriptional repressor ETV6 (ETS translocation variant 6). In this study, we investigated the growth-inhibitory effect of STI571 (signal transduction inhibitor number 571) on ETV6/ARGexpressing cells and its molecular mechanisms using HT93A, a cell line derived from a patient with AML-M3 carrying t(1;12). STI571 effectively suppressed overall tyrosyl phosphorylation of intracellular proteins including ETV6/ARG fusion protein, as well as the growth of HT93A cells with an IC 50 of 200 nm. The growth inhibition was primarily because of cell cycle arrest at G1 phase when cells were treated with 100 nm STI571 for 48 h, and apoptosis was induced after longer exposure (72 h) or by a higher dose (1000 nm). STI571 increased the amount of p18/INK4c after 2 h of culture, when the cell cycle pattern was not yet affected, but not that of other CDK inhibitors (CKI). p18/INK4c was more abundant in G1-enriched fractions than in S-and G2/Menriched fractions of STI571-treated HT93A cells, suggesting that the upregulation of p18/INK4c expression correlates with the cell cycle arrest. Treatment of HT93A cells with antisense oligonucleotides against the Ink4c gene abrogated the growth inhibition by STI571. These results suggest that leukemogenesis by an aberrant ARG kinase involves the suppression of p18/INK4c, which is ubiquitously expressed and considered the major CKI in hematopoietic stem cells. STI571 can be an effective drug for the treatment of leukemias with deregulated ARG kinase activity.
Introduction
Tyrosine kinases are known to regulate several cellular processes including proliferation, differentiation, and survival as the principal modulators of signal transduction in normal cells (Hubbard and Till, 2000) . As the deregulation of tyrosine kinases plays a crucial role in malignant transformation in various forms of human cancer, tyrosine kinase inhibitors are expected to be ideal for cancer treatment. However, it is difficult to achieve specificity of inhibition, because kinase domains are conserved widely among tyrosine kinases. The first synthetic tyrosine kinase inhibitor, tyrphostin, was developed in 1988 (Yaish et al., 1988) . This drug showed only limited specificity and efficacy, but led to the development of a more specific inhibitor called STI571 (signal transduction inhibitor number 571).
STI571, now available as Gleevect, is a small molecule that inhibits ABL tyrosine kinase by occupying the kinase pocket and blocking access to ATP, thereby preventing phosphorylation of its substrates (Druker et al., 1996; Schindler et al., 2000) . STI571 has been shown to inhibit the members of the abl gene family, including c-ABL and BCR/ABL, as well as c-KIT and the platelet-derived growth factor (PDGF) b receptor without affecting other tyrosine kinases in vitro (Druker et al., 1996; Druker and Lydon, 2000) . Indeed, the results of recent clinical trials proved that STI571 is highly effective against diseases with deregulated tyrosine kinase activity, such as BCR/ABL-positive leukemias, gastrointestinal stromal tumors expressing c-KIT, and glioblastomas expressing PDGFb receptor, with minimal harmful effects (Druker et al., 2001a, b; Joensuu et al., 2001) .
ARG is an abl-related gene product with striking similarity to c-ABL at the SH3, SH2, and kinase domains, and expresses widely in normal cells (Krush et al., 1986; Perego et al., 1991) . Further study showed that ARG is also implicated in leukemogenesis; the fusion between ARG and ETV6 (ETS translocation variant 6), also known as TEL (translocation ETS leukemia), was identified in two independent cases of human leukemias with a t(1;12)(q25;p13) translocation (Cazzaniga et al., 1999; Iijima et al., 2000) and in a T-lymphoblastic cell line derived from a patient with acute lymphoid leukemia carrying t(1;10;12)(q25;q23;p13) (Griesinger F, personal communication). ETV6, a transcriptional repressor of the ets gene family, is known as a fusion partner of various tyrosine kinases including PDGF receptor (Golub et al., 1994) , c-ABL (Andreasson et al., 1997) , JAK2 (Lacronique et al., 1997) , and TRKC (Eguchi et al., 1999) . These fusion proteins possess constitutive tyrosine kinase activity, which accelerates the entry of hematopoietic cells into the cell cycle, leading to leukemogenesis. Recent investigation demonstrated that ETV6/ARG is also oncogenic; it can confer IL-3 independence to an IL-3-dependent murine hematopoietic cell line Ba/F3, and is capable of transforming Rat-1 fibroblasts (Iijima et al., 2002) .
Given the sequence similarity, it is easy to speculate that ARG kinase and its oncogenic form, ETV6/ARG, are possible targets of STI571. Recently, Okuda et al. (2001) reported that STI571 inhibits cellular tyrosine phosphorylation and induces apoptosis in Ba/F3 cells transfected with ETV6/ARG. Although their data clearly show that ARG is a target of STI571 in the murine model system, further study is required to confirm this finding in human leukemic cells. It is also important to elucidate the mechanisms of STI571-mediated growth inhibition and/or apoptosis of ETV6/ ARG-transformed cells for clinical application in the future. In this study, we investigated the growthinhibitory effect of STI571 on ETV6/ARG-expressing cells and its molecular mechanisms using HT93A, a cell line derived from an AML-M3 patient carrying t(1;12). We found that suppression of ARG kinase activity by STI571 induced cell cycle arrest through upregulation of the CDK inhibitor p18/INK4c in HT93A cells.
Materials and methods

Reagents
All chemicals were purchased from Sigma Chemical Co. (St Louis, MO, USA) unless otherwise stated. STI571 was provided by Novartis Pharma (Basel, Switzerland). Morpholino antisense oligonucleotides against the human Ink4c gene and its scrambled control were purchased from Gene Tools, LLC (Philomath, OR, USA).
Cells and cell separation
The human acute promyelocytic leukemia cell line HT93A was established from the peripheral blood of a patient with acute promyeloblastic leukemia (Kishi et al., 1998) . Previous studies revealed that this cell line carries t(1;12)(q25;p13) and expresses an ETV6/ARG fusion protein in addition to t(15;17)(q22; q11) with a short-type PML/RARa transcript (Iijima et al., 2000) . We used four BCR/ABL-positive cell lines, KU812, K562, TCC-S, and TCC-Y, as controls (Kano et al., 2001) . KU812, K562, and TCC-S were established from patients with chronic myelogenous leukemia in myeloblastic crisis, and TCC-Y was derived from a patient with Philadelphia-chromosome-positive acute lymphoblastic leukemia. These cell lines were maintained in RPMI1640 medium supplemented with 10% fetal bovine serum. Separation of cells enriched for each phase of the cell cycle was conducted with counterflow centrifugal elutriation using the SRR6Y system (Hitachi Koki Co., Tokyo, Japan) as previously described (Terui et al., 1995) .
Cell culture
The IC 50 of STI571 for HT93A was determined by MTT reduction assay as reported previously (Kano et al., 2001) . For the delivery of oligonucleotides into cells, HT93A cells (5 Â 10 5 cells/ml) were treated with either H 2 O, antisense oligonucleotides or control oligonucleotides at 1.4 mm in the presence of 560 nm ethoxylated polyethylenimine for 3 h (Morcos, 2001) . Cells were then washed, resuspended at 2 Â 10 5 cells/ml in RPMI1640 medium supplemented with 10% fetal calf serum, and cultured in the absence or presence of 100 nm STI571 for 2 days. To evaluate the effect of antisense oligonucleotides, we used cell cycle analysis on flow cytometry and [ 
Flow cytometry
The cell cycle profile was determined by staining DNA with propidium iodide in preparation for flow cytometry with the FACScan/CellQuest system (Becton-Dickinson, San Jose, CA, USA). The size of the sub-G1, G0/G1, and S+G2/M fractions was calculated as a percentage by analysing DNA histograms with the ModFitLT 2.0 program (Verity Software, Topsham, ME, USA). Cells undergoing apoptosis were detected by staining with Annexin-V-Alexa 568 (Roche Diagnostics, Mannheim, Germany).
Western blotting
Immunoblotting was carried out according to the standard method using the following antibodies: antiphosphotyrosine (PY20; ICN Biochemicals, Aurora, OH, USA), anti-CDK2 (M2; Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-CDK4 (clone 97; Transduction Laboratories, Lexington, KY, USA), anti-CDK6 (B-10; Santa Cruz Biotechnology), antiCyclin A (BF683; Pharmingen, San Diego, CA, USA), antiCyclin D1 (clone 105; Transduction Laboratories), anti-Cyclin D2 (clone G132-43; Pharmingen), anti-Cyclin D3 (clone 1; Transduction Laboratories), anti-Cyclin E (C-20; Santa Cruz Biotechnology), anti-p16/INK4a (G175-1239; Pharmingen), anti-p15/INK4b (R-20; Santa Cruz Biotechnology), anti-p18/ INK4c (118.2; Santa Cruz Biotechnology), anti-p19/INK4d (DCS100.1F7; Oncogene Research Products, Cambridge, MA, USA), anti-p21/Cip1 (clone 70; Transduction Laboratories), anti-p27/Kip1 (clone 57; Transduction Laboratories), antip57/Kip2 (C-20; Santa Cruz Biotechnology), and anti-b-actin (Ab-1; Oncogene Science, Uniondale, NY, USA).
Immunoprecipitation and RB kinase assay
Whole-cell lysates (300 mg) were incubated with 5 ml of anti-CDK4 antibody or preimmune mouse IgG in 300 ml of IP buffer (50 mm HEPES, pH 7.5, 150 mm NaCl, 1 mm EDTA, 2.5 mm EGTA, 0.1% Tween-20, 10% glycerol) at 41C for 1 h. Immune complexes were collected on protein A/G-sepharose beads, washed three times in 0.5 Â IP buffer, and resuspended in 25 ml of kinase buffer containing 20 mm Tris-HCl (pH 7.4), 10 mm MgCl 2 , 1 mm EGTA, 4.5 mm 2-mercaptoethanol, 50 mm ATP, and 15 mCi [g-32 P]ATP in the presence of pRB-GST fusion protein (nt 385-928) (Saijo et al., 1994) . After incubating for 30 min at 301C, the samples were resolved on 8% SDS-polyacrylamide gel electrophoresis, followed by Coomassie brilliant blue staining and autoradiography. To examine the phosphorylation status of ETV6/ARG fusion protein, immunoprecipitation was carried out with rabbit anti-ETV6 antibody (H-214; Santa Cruz Biotechnology), followed by immunoblotting with goat anti-ARG antibody (C-20; Santa Cruz Biotechnology) and mouse antiphosphotyrosine antibody (PY20).
Northern blotting
An equal amount (15 mg) of total cellular RNA was electrophoresed in 1% agarose gels containing formaldehyde, and blotted onto Hybond N + synthetic nylon membranes (Amersham Pharmacia Biotech., Buckinghamshire, England). The membranes were hybridized with a 32 P-labeled fragment of p18/Ink4c (nt 1367-1679) cDNA (Guan et al., 1994) in Rapidhyb buffer (Amersham Pharmacia Biotech.).
Results
STI571 induced cell cycle arrest in HT93A cells at clinically achievable concentrations
To investigate whether STI571 could inhibit the activity of ETV6/ARG in vivo, we first examined the effects of STI571 on the growth of HT93A cells. HT93A cells were cultured with clinically relevant concentrations (0-10 000 nm) of STI571 based on published data of pharmacokinetics (Mauro and Druker, 2001) , and cell numbers were determined by MTT reduction assay after 5 days. The IC 50 of STI571 for HT93A cells was calculated to be 200 nm (Figure 1) . The decrease in cell number was confirmed by other methods including [ 3 H]thymidine incorporation and direct cell counting (data not shown). Based on this data, we decided to use 100 and 1000 nm for the experiments in this study. At 1000 nm, STI571 almost completely suppressed the autophosphorylation of ETV6/ARG fusion protein without affecting its abundance in HT93A cells (Figure 2a ). Tyrosyl phosphorylation of intracellular proteins was significantly inhibited by STI571 at 100 nm and became almost undetectable at 1000 nm (Figure 2b) .
In order to clarify the mechanisms underlying the decrease in cell number, we analysed the cell cycle profile of HT93A cells after 0, 12, 24, and 48 h of culture with 100 nm STI571. Representative DNA histograms are shown in Figure 3 , and the results of three independent experiments are summarized in Table 1 . The culture of cells with 100 nm STI571 resulted in cell cycle arrest at G0/G1. The proportion of cells in the sub-G1 phase remained less than 5% after exposure to 100 nm STI571 up to 48 h, suggesting that apoptosis is not the major mechanism of STI571-induced growth arrest in HT93A cells. However, Annexin-V staining revealed that apoptosis was induced after longer exposure (72 h) and by a higher dose (1000 nm) of the drug (Table 2) .
STI571 induced upregulation of p18/INK4c in HT93A cells
Next, we screened for the expression of cell cycle control elements to clarify the mechanisms underlying the STI571-induced G1 arrest of HT93A cells. Whole-cell lysates were isolated at 0, 2, 6, 12, and 24 h of culture with 100 nm SIT571, and subjected to immunoblotting for various cell cycle regulatory proteins. Among the CDKs and cyclins involved in the G1/S transition in higher eucaryotic cells, STI571 slightly reduced the amounts of CDK2, and Cyclins A, D3, and E (Figure 4a ), whereas the abundance of CDK4, CDK6, and Cyclins D1 and D2 was unchanged or below the detection limit (data not shown). Among CDK inhibitors examined, STI571 did not affect or only slightly (Figure 4b) . To determine the causal relation between the accumulation of p18/INK4c and cell cycle arrest, we compared the levels of p18/ INK4c between G0/G1-and S+G2/M-enriched fractions separated from HT93A cells cultured with STI571 for 24 h. As shown in Figure 5 , the amounts of p18/ INK4c were obviously larger in fractions 1 and 2, which consisted of more than 70% G0/G1-arrested cells, than in Fractions 4 and 5, which contained less than 50% of cells in G0/G1 phase. Taken together, these results indicate that the upregulation of p18/INK4c correlates with the growth-inhibitory effect of STI571 on HT93A cells.
Upregulation of p18/INK4c occurred at both the mRNA and protein levels
To further confirm the induction of p18/INK4c by STI571, we performed Northern blot analysis for Ink4c mRNA expression in HT93A cells. The Ink4c gene is known to generate two mRNA transcripts, which are different in size (2.4 and 1.2 kb) and function. It has been reported that the 1.2 kb transcript is more efficiently translated than the 2.4 kb transcript, and is specifically induced during terminal differentiation of various tissues (Phelps et al., 1998) . As shown in Figure 6 , the 2.4 Ink4c transcript was constitutively expressed in HT93A cells, and its abundance was not affected by STI571. In contrast, the 1.2 kb transcript was not present in untreated HT93A cells, but became faintly detectable after 6 h of culture with 1000 nm STI571. The signal intensity increased in a time-and dose-dependent manner, which confirms STI571-induced upregulation of p18/INK4c at the mRNA level. As p18/INK4c protein was readily upregulated before the appearance of the 1.2 kb transcript, it is highly likely Antisense oligonucleotides against p18/Ink4c abrogated the growth-inhibitory effect of STI571 on HT93A cells
Finally, we examined whether the growth-inhibitory effect of STI571 on HT93A cells was affected by blocking the induction of p18/INK4c. To this end, HT93A cells were pretreated with antisense oligonucleotides against the Ink4c gene or its scrambled control, and cultured in the absence or presence of STI571. The effect of antisense oligonucleotides was confirmed by monitoring p18/INK4c levels using immunoblotting. As anticipated, antisense but not control oligonucleotides effectively blocked STI571-induced upregulation of p18/ INK4c (Figure 7a) . Furthermore, the inhibition of p18/ INK4c expression was associated with the abrogation of STI571-mediated suppression of CDK2 and Cyclins A, D3, and E (Figure 7a ), suggesting that the induction of p18/INK4c is a primary event among the changes in cell cycle regulatory elements. Next, we examined the effects of antisense oligonucleotides on cell cycle profile of HT93A cells. Figure 7b shows a representative result of cell cycle analysis after 2 days. As is clearly shown, the STI571-induced G0/G1 arrest was canceled by blocking the induction of p18/ INK4c with antisense oligonucleotides, whereas control oligonucleotides did not change the effect of STI571. This was confirmed by [ 3 H]thymidine incorporation assay (Figure 7c ). These results are fully compatible with our finding that p18/INK4c is a major mediator of the cell cycle arrest in STI571-treated HT93A cells.
Discussion
Intervention of aberrant tyrosine kinase activities may be an ideal mode of cancer therapy if achieved in a Upregulation of p18/INK4c by STI571 N Nishimura et al specific way. Recently, specific inhibitors for tyrosine kinases were developed, and some of them have already been applied clinically (Schiffer, 2001) . The most prominent example of such inhibitors is STI571, which is now widely used for the treatment of BCR/ABLpositive leukemias with great success (Druker et al., 2001a, b) . In addition to ABL, STI571 is known to inhibit the activities of c-KIT, PDGF receptor, and, most recently, c-ARG (Okuda et al., 2001) . Although it is established that STI571 targets ARG kinase, little is known about the cellular consequences as well as the mechanisms of inhibition. In this study, with this background in mind, we investigated the growthinhibitory effect of STI571 on cells carrying ETV6/ ARG, an oncogenic form of ARG, and its molecular mechanisms using an AML cell line with a t(1; 12) translocation (Iijima et al., 2000) . As anticipated, STI571 effectively suppressed overall tyrosyl phosphorylation of intracellular proteins including ETV6/ARG fusion protein as well as the growth of HT93A cells at clinically achievable concentrations, and its IC 50 was calculated to be 200 nm. This confirms previous results from experiments using a murine factordependent cell line transfected with ETV6/ARG (Okuda et al., 2001) , and encourages further application of STI571 to treat malignancies caused by aberrant ARG kinases. The growth inhibition of HT93A cells was primarily because of cell cycle arrest at G1 phase, and apoptosis was induced after longer exposure or by higher doses of STI571. We then investigated the molecular basis of the STI571-induced G1 arrest, and found that STI571 increased the amount of p18/INK4c but not other CKIs after 2 h of culture, when cell cycling was not yet perturbed. Although STI571 decreased the abundance of some positive regulators of the cell cycle such as CDK2, and Cyclins A, D3 and E, we believe that upregulation of p18/INK4c is the principal mechanism of STI571-induced G1 arrest for two reasons. First, p18/ INK4c was more abundantly expressed in G1-enriched fractions than in S-and G2/M-enriched fractions of STI571-treated HT93A cells. Second, treatment of HT93A cells with antisense oligonucleotides against the Ink4c gene almost completely abrogated the growthinhibitory effect of STI571 as well as the changes in other cell cycle regulators.
p18/INK4c was originally identified as one of the cellular proteins physiologically associated with D-type cyclin-dependent kinases, and cloned by yeast interaction screening in 1994 (Guan et al., 1994) . Since mutations of the Ink4c gene are relatively rare in human cancers (Drexler, 1998) , the biological characterization of p18/INK4c is not fully conducted compared with other members of the INK4 family. Recent investigations, however, revealed that p18/INK4c is ubiquitously expressed in normal tissues (Thullberg et al., 2000) , and also abundant in CD34 + hematopoietic progenitor cells (Tschan et al., 1999) . p18/INK4c downregulates along with myeloid differentiation, and became undetectable in mature granulocytes and monocytes (Tschan et al., 1999) . It has been reported that p18/INK4c is a downstream target of interleukin-6, and plays a role in exit from the cell cycle during terminal differentiation of B-lymphocytes (Morse et al., 1997) . The expression pattern and function of p18/INK4c are fully consistent with the present observations. The causal relation between the suppression of ETV6/ARG and upregulation of p18/INK4c strongly suggests that the leukemogenesis caused by an aberrant ARG kinase involves the suppression of p18/INK4c, which normally acts to inhibit cell cycle progression and facilitate differentiation of hematopoietic stem cells.
According to recent investigations, the mechanisms of STI571-mediated growth suppression of BCR/ABLpositive leukemias can be divided into two categories; (i) cell cycle arrest and (ii) induction of apoptosis (Fang et al., 2000; Horita et al., 2000; Oetzel et al., 2000) . As for the former, it has been reported that STI571 rapidly increases the levels of p27/Kip1 in Bcr/Abl-transfected cell lines (Gesbert et al., 2000; Jonuleit et al., 2000) . The induction of p27/Kip1 expression is considered to be mediated through the suppression of proteasomedependent degradation accelerated by BCR/ABL, although an increase in Kip1 mRNA was reported by Parada et al. (2001) . In addition, they described downregulation of Cyclin D2, Cyclin D3, and p21/Cip1 in the absence of IL-3 in an IL-3-dependent cell line expressing BCR/ABL (Parada et al., 2001 ). To our knowledge, there is no paper dealing with the effect of STI571 on p18/INK4c expression in BCR/ABL-positive cells. We therefore examined the expression of p18/INK4c in KU812, a leukemia cell line established from a patient with CML in blastic crisis, cultured with 100 nm STI571. p18/INK4c was barely detectable in untreated KU812 cells, and was not induced after STI571 treatment, although upregulation of p27/Kip1 was observed in accordance with previous studies (data not shown). Taking into account the fact that STI571 did not increase the levels of p27/Kip1 in HT93A cells, STI571 may induce cell cycle arrest via distinct mechanisms in cells transformed by oncogenic forms of ABL and ARG. This also suggests that the underlying mechanisms of leukemogenesis are different between BCR/ABL and ETV6/ARG. Our findings may provide a clue as to the signal transduction pathways downstream of the ARG kinase, and how abnormalities therein contribute to the transformation of hematopoietic stem cells.
